A carregar...
Rethinking the combination treatment of fulvestrant and anastrozole for metastatic breast cancer: an integrated reanalysis of aromatase–estrogen receptor axis
Aberrant expression or hyperactivation of aromatase (CYP19A1)–estrogen receptor (ESR) axis is well identified as one of the major causes of breast cancer. Lots of drugs have been developed for targeting CYP19A1 or ESR respectively, such as anastrozole and fulvestrant. Recently, Mehta et al. reported...
Na minha lista:
| Publicado no: | Clin Transl Med |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Berlin Heidelberg
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6861394/ https://ncbi.nlm.nih.gov/pubmed/31741086 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40169-019-0246-5 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|